why choose us

First received: February 20, 2023

Clinical Trial: A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Nonsegmental Vitiligo With Genital Involvement

Study Type: INTERVENTIONAL


Official Title: An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo

Brief Summary: An open-label study in which participants with non-segmental vitiligo with genital involvement will apply ruxolitinib 1.5% cream twice a day (BID) to all depigmented areas (up to 10% BSA) for up to 48 weeks.Participants should continue to treat depigmented areas identified for treatment at baseline regardless of whether the area begins to improve or fully repigment.

Read more